The road to the $50 program: a policy timeline
Short answer: Medicare's journey with GLP-1s runs from a statutory ban — Part D was written to exclude weight-loss drugs entirely — through years of workarounds by indication (diabetes, then heart disease, sleep apnea, and MASH), to the BALANCE Model's stall and the Bridge demonstration launched July 1, 2026. Each step explains a rule Bridge patients live with today.
Program facts last verified against CMS: July 21, 2026
The milestones that matter
The foundation: Part D's 2003 statute excluded weight-loss drugs from coverage — the root of everything since. The workaround era: GLP-1s entered Medicare through non-weight indications — diabetes coverage for products like Ozempic; then Wegovy's 2024 cardiovascular indication cracked the door for heart patients; Zepbound's sleep-apnea approval and semaglutide's MASH approval followed the same pattern. Each indication-based path is why the Bridge's 'exclusion' diagnoses exist: those patients already had coverage routes.
The direct-coverage era: CMS designed BALANCE to bring weight-loss coverage into Part D plans voluntarily; plan participation fell short, the Medicare component was postponed in April 2026, and the Bridge — announced as a shorter program and extended to eighteen months — launched July 1, 2026 as the first direct Medicare coverage of GLP-1s for weight loss alone. Its December 31, 2027 end date is where the timeline currently stops; our extension tracker watches the next entry.
Take the 2-minute eligibility check →
Common questions
Why did Part D ever exclude weight-loss drugs?
The 2003 statute reflected its era: weight-loss drugs then had a troubled safety history and were viewed as lifestyle products. The clinical picture changed; the statute didn't — hence two decades of workarounds.
Which came first, the Bridge or BALANCE?
BALANCE was announced as the plan; the Bridge was created as its stopgap and then extended when BALANCE's Medicare component stalled. The Bridge is the interim that outlived its successor's launch date.
Does this history predict what happens in 2028?
It frames the possibilities: statutory change (permanent), another demonstration (temporary), or reversion to indication-based coverage only. The recurring obstacle in every chapter is the same — cost.
Related
Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF